Castle Biosciences Inc

NASDAQ:CSTL  
63.58
-1.52 (-2.34%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.28B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$22.97 Million
Adjusted EPS-$0.40
See more estimates
10-Day MA$64.09
50-Day MA$69.47
200-Day MA$70.06
See more pivots

Castle Biosciences Inc Stock, NASDAQ:CSTL

820 South Friendswood Drive, Suite 201, Friendswood, Texas 77546
United States of America
Phone: +1.866.788.9007
Number of Employees: 201

Description

Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.